Loading clinical trials...
Loading clinical trials...
Personalized Memory Enhancement in Aging: Pattern-Optimized tACS With Closed-Loop Precision Modulation
This project optimizes high-resolution tACS to improve memory in healthy older adults, advancing drug-free approaches for ADRD. We test stimulation schedules and develop an adaptive, brain-guided tACS system to strengthen memory-supporting networks.
Cognitive decline, especially in memory and executive control, poses an escalating public health challenge as the population ages, contributing to loss of independence, reduced quality of life, and increased healthcare costs associated with Alzheimer's disease and related dementias (ADRD). Despite decades of research, there are few effective, non-pharmacological interventions capable of slowing or reversing these cognitive losses. Transcranial alternating current stimulation (tACS) has recently emerged as a promising, safe, and non-invasive technique for modulating neural rhythms that support memory. However, existing approaches remain limited by one-size-fits-all stimulation schedules that fail to account for individual brain connectivity patterns or dynamic fluctuations in cognitive state. This project aims to advance precision neuromodulation for cognitive aging by optimizing and personalizing high-resolution tACS protocols to enhance memory in older adults. Building on strong pilot data demonstrating the feasibility of personalized and adaptive stimulation, we will use multimodal imaging (EEG and fMRI) to track changes in frontotemporal synchrony, specifically theta-gamma phase-amplitude coupling and theta phase synchronization, that are known to support memory formation and retrieval. Aim 1 will establish how stimulation pattern (patterned vs. continuous waveforms) and schedule (one, three, or five consecutive days) shape the durability of memory enhancement. By comparing six systematically varied dosing protocols, we will determine the optimal pattern and repetition schedule that maximize and sustain improvements in working memory capacity, interference control, and long-term memory recognition over one month. Aim 2 will develop and test a connectivity-guided closed-loop tACS system that continuously monitors neural synchronization in the frontotemporal network and adjusts stimulation parameters in real time. This adaptive framework is designed to tailor stimulation to each participant's evolving brain state, enabling more efficient and individualized cognitive enhancement than static approaches. By integrating behavioral, electrophysiological, and neuroimaging measures with adaptive control algorithms, this research will identify reliable biomarkers of responsiveness, elucidate causal mechanisms linking neural synchrony to memory, and yield a new class of personalized, connectivity-guided interventions for cognitive decline. The findings will lay a foundation for scalable, non-invasive, and mechanism-driven treatments for ADRD and age-related memory loss, advancing the broader NIH mission of promoting healthy cognitive aging.
Age
65 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Start Date
March 15, 2026
Primary Completion Date
January 31, 2031
Completion Date
January 31, 2031
Last Updated
March 10, 2026
400
ESTIMATED participants
1-day patterned tACS
DEVICE
3-day patterned tACS
DEVICE
5-day patterned tACS
DEVICE
1-day continuous tACS
DEVICE
3-day continuous tACS
DEVICE
5-day continuous tACS
DEVICE
Lead Sponsor
Boston University Charles River Campus
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions